{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"}]}],"title":"Cycle 1 - Baseline (n=80,80))"},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.9"},{"groupId":"OG001","value":"31.1"}]}],"title":"Cycle 2 - Pre-dose (n=71, 74)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3"},{"groupId":"OG001","value":"37.9"}]}],"title":"Cycle 2 - Post-dose (n=65, 66)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.2"},{"groupId":"OG001","value":"30.5"}]}],"title":"Cycle 2 Day 2 (n=54, 59)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0"},{"groupId":"OG001","value":"37.0"}]}],"title":"Cycle 2 Day 3 (n=48, 54)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1"},{"groupId":"OG001","value":"76.5"}]}],"title":"Cycle 3 Day 1 (n=67,68)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.1"},{"groupId":"OG001","value":"84.1"}]}],"title":"Cycle 4 Day 1 (n=71,69)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.2"},{"groupId":"OG001","value":"89.6"}]}],"title":"Cycle 5 Day 1 (n=68,67)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8"},{"groupId":"OG001","value":"95.3"}]}],"title":"Cycle 6 Day 1 (n=71,64)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5"},{"groupId":"OG001","value":"96.9"}]}],"title":"FU 28 Day Visit (n=66,64)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.1"},{"groupId":"OG001","value":"97.0"}]}],"title":"FU 56 Day Visit (n=63,67)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.5"},{"groupId":"OG001","value":"92.5"}]}],"title":"FU 3 Month Visit (n=67,67)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.3"},{"groupId":"OG001","value":"91.3"}]}],"title":"FU 6 Month Visit (n=60,69)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.2"},{"groupId":"OG001","value":"70.3"}]}],"title":"FU 9 Month Visit (n=65,64)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.3"},{"groupId":"OG001","value":"42.6"}]}],"title":"FU 12 Month Visit (n=60,61)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.9"},{"groupId":"OG001","value":"30.0"}]}],"title":"FU 15 Month Visit (n=59,60)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.6"},{"groupId":"OG001","value":"25.9"}]}],"title":"FU 18 Month Visit (n=57,58)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5"},{"groupId":"OG001","value":"19.2"}]}],"title":"FU 21 Month Visit (n=55,52)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7"},{"groupId":"OG001","value":"15.7"}]}],"title":"FU 24 Month Visit (n=56,51)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.2"},{"groupId":"OG001","value":"73.3"}]}],"title":"Withdrawn/Termination (n=17,15)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"85"}],"units":"Participants"}],"description":"Total B-cell depletion (normal B-cell plus Malignant B-cell depletion) was defined for each individual participant when the sum of CD5-/CD19+ (normal B-cells) and CD5+/CD19+ (malignant B-cells) cell counts decreased below 80 cells/μL.","groups":[{"description":"Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 0 Cycles 2-6: IV rituximab 500 mg/m\\^2 on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG000","title":"Part 2 : Rituximab IV 500 mg/m^2"},{"description":"Participants received the following in 28-day cycles. Cycle 1: IV rituximab 375 mg/m\\^2 on Day 0 Cycles 2-6: SC rituximab 1600 mg on Day 1 Cycles 1-6: IV fludarabine 25 mg/m\\^2 on Days 1-3 (or as an oral dose of 24 mg/m\\^2 on Days 1-5 or 30-40 mg/m\\^2 on Days 1-3), and IV cyclophosphamide 250 mg/m\\^2 on Days 1-3 (or as an oral dose of 150 mg/m\\^2 on Days 1-5 or 200-250 mg/m\\^2 on Days 1-3).","id":"OG001","title":"Part 2: Rituximab SC 1600 mg"}],"paramType":"NUMBER","populationDescription":"Part 2 SAP; n= number of participants analyzed at the specified visit.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Pre-dose, 60 minutes post-dose, Days 2 and 3 in Cycle 2, day 1 in Cycles 3, 4, 5 and 6, Follow-up Days 28 and 56, and Follow-up Visits at Months 3, 6, 9, 12, 15, and 18 and Withdrawal Visit","title":"Part 2: Percentage of Participants With Total B-Cell Depletion by Visit","type":"SECONDARY","unitOfMeasure":"percentage of participants"}